NEFL and neurodegenerative disease: This study is the first demonstration that masitinib can lower serum NfL levels in a neuroimmune-driven neurodegenerative disease model, with concomitant reduction in pro-inflammatory cytokines and slowing of clinical (EAE) symptoms.